Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

NOBUAKI ISHIHARA; SHOHEI KOMATSU; YOSHIHIKO YANO; YOSHIMI FUJISHIMA; JUN ISHIDA; MASAHIRO KIDO; HIDETOSHI GON; KENJI FUKUSHIMA; TAKESHI URADE; TOSHIHIKO YOSHIDA; KENTARO TAI; KEISUKE ARAI; HIROAKI YANAGIMOTO; HIROCHIKA TOYAMA; TAKANORI MATSUURA; TOSHIFUMI TADA; YUZO KODAMA; TAKUMI FUKUMOTO

doi:10.21873/anticanres.17412

Research ArticleClinical Studies

Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

NOBUAKI ISHIHARA, SHOHEI KOMATSU, YOSHIHIKO YANO, YOSHIMI FUJISHIMA, JUN ISHIDA, MASAHIRO KIDO, HIDETOSHI GON, KENJI FUKUSHIMA, TAKESHI URADE, TOSHIHIKO YOSHIDA, KENTARO TAI, KEISUKE ARAI, HIROAKI YANAGIMOTO, HIROCHIKA TOYAMA, TAKANORI MATSUURA, TOSHIFUMI TADA, YUZO KODAMA and TAKUMI FUKUMOTO

Anticancer Research January 2025, 45 (1) 251-260; DOI: https://doi.org/10.21873/anticanres.17412

NOBUAKI ISHIHARA

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

SHOHEI KOMATSU

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: komasho8{at}med.kobe-u.ac.jp

YOSHIHIKO YANO

2Department of Internal Medicine, Division of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YOSHIMI FUJISHIMA

3Division of Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

JUN ISHIDA

4Division of Radiology, Kobe Minimally Invasive Cancer Center, Kobe, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MASAHIRO KIDO

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HIDETOSHI GON

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KENJI FUKUSHIMA

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TAKESHI URADE

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TOSHIHIKO YOSHIDA

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KENTARO TAI

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KEISUKE ARAI

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HIROAKI YANAGIMOTO

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HIROCHIKA TOYAMA

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TAKANORI MATSUURA

2Department of Internal Medicine, Division of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TOSHIFUMI TADA

2Department of Internal Medicine, Division of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YUZO KODAMA

2Department of Internal Medicine, Division of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TAKUMI FUKUMOTO

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles

PreviousNext

In this issue

Anticancer Research

Vol. 45, Issue 1

January 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 3 + 0 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

Anticancer Research Jan 2025, 45 (1) 251-260; DOI: 10.21873/anticanres.17412

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

Anticancer Research Jan 2025, 45 (1) 251-260; DOI: 10.21873/anticanres.17412

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Cited By...

Macrophage-related Genomic Signatures Predict HCC Prognosis and Therapy Response
Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab-Durvalumab
Mid-term Combination Immunotherapy and its Effect on the Albumin-Bilirubin Score in Unresectable Hepatocellular Carcinoma

Google Scholar

Keywords

Hepatocellular carcinoma
drug sequence
Atezolizumab plus bevacizumab
tyrosine kinase inhibitor
durvalumab plus tremelimumab

Main menu

User menu

Search

Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

Purchase access

patientACCESS

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Keywords